Published in Ann Neurol on December 01, 2010
Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology (2014) 2.64
Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology (2013) 2.24
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology (2013) 1.56
Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol (2011) 1.11
Should Hypersexual Disorder be Classified as an Addiction? Sex Addict Compulsivity (2013) 1.05
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.90
Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord (2013) 0.88
Multiple modes of impulsivity in Parkinson's disease. PLoS One (2014) 0.87
Available and emerging treatments for Parkinson's disease: a review. Drug Des Devel Ther (2011) 0.87
Treatment of Gambling Disorders. Curr Treat Options Psychiatry (2014) 0.84
Pathological Gambling: Neuropsychopharmacology and Treatment. Curr Psychopharmacol (2012) 0.84
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Mov Disord (2015) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin Psychol (2013) 0.82
Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord (2013) 0.80
Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. J Neurol (2014) 0.79
Impulse control disorders in Parkinson's disease: background and update on prevention and management. Neurodegener Dis Manag (2012) 0.79
Repetitive transcranial magnetic stimulation transiently reduces punding in Parkinson's disease: a preliminary study. J Neural Transm (Vienna) (2013) 0.78
Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord (2013) 0.78
Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology update. J Mov Disord (2014) 0.76
Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives. Biomed Res Int (2014) 0.76
Neuropsychiatric symptoms in untreated Parkinson's disease. Neuropsychiatr Dis Treat (2017) 0.75
Treatment modalities for patients with gambling disorder. Ann Gen Psychiatry (2017) 0.75
Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications. P T (2015) 0.75
Parkinson disease: Amantadine administration is associated with impulse control disorders in PD. Nat Rev Neurol (2011) 0.75
Impulsive and Compulsive Behaviors in Parkinson Disease: The Norwegian ParkWest Study. J Parkinsons Dis (2016) 0.75
Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease. CNS Drugs (2017) 0.75
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry (2003) 7.11
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Can food be addictive? Public health and policy implications. Addiction (2011) 6.27
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend (2006) 3.61
Compulsive features in behavioural addictions: the case of pathological gambling. Addiction (2011) 3.28
Introduction to behavioral addictions. Am J Drug Alcohol Abuse (2010) 3.22
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology (2009) 2.60
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Mindfulness-based treatments for co-occurring depression and substance use disorders: what can we learn from the brain? Addiction (2010) 2.50
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry (2006) 2.50
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Preliminary validity and reliability testing of a structured clinical interview for pathological gambling. Psychiatry Res (2004) 2.35
Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology (2006) 2.32
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol (2007) 2.22
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Broadening our horizon: response to commentaries. Addiction (2012) 2.11
Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry (2005) 2.09
Health correlates of recreational gambling in older adults. Am J Psychiatry (2004) 2.08
Pretreatment brain activation during stroop task is associated with outcomes in cocaine-dependent patients. Biol Psychiatry (2008) 2.04
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Gender differences in the associations between past-year gambling problems and psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol (2007) 2.02
Psychopathology and psychogenic movement disorders. Mov Disord (2011) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc (2008) 1.92
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol (2009) 1.90
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) (2011) 1.77
Deep brain stimulation: preoperative issues. Mov Disord (2006) 1.77
Problematic Internet use: clinical implications. CNS Spectr (2007) 1.74
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry (2009) 1.70
Psychiatric correlates of gambling in adolescents and young adults grouped by age at gambling onset. Arch Gen Psychiatry (2004) 1.68
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol (2013) 1.64
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63